title: The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
abstract: OBJECTIVE
  Though serum p53 antibody has been widely used, it is mentioned that it is not related to clinical parameters of colorectal cancer (CRC) and has no prognostic significance in long-term follow-up. The aim of this study was to explore the possibility to increase the value of p53 antibody in combination with carcinoembryonic antigen (CEA) and CA19-9 for post operation follow up.
  
  
  METHODS
  One hundred twenty-eight patients with primary CRC who underwent surgery were enrolled in this study. Serum p53 antibodies, CEA and CA19-9 were measured before and after the surgery and their impact on CRC staging patient survival. DNA was extracted from colorectal cancer tissue and KRAS mutation analysis was determined by direct sequencing.
  
  
  RESULTS
  Thirty seven point five patients were positive for serum p53 antibodies before the operation. Total 67.2% patients were positive with any tumor markers, but it was only 3.9% that were positive with all markers. There was no association between KRAS mutation and p53 antibody level.
  
  
  CONCLUSIONS
  The combined use of tumor markers can be an effective screening method for detection of colorectal cancer. If serum p53 antibody level continues to be positive for long after resection, the case should require subsequent intense follow-up.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kawahara
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Fujita
authors.forename: Hideki
authors.initials: H
authors.lastname: Hayashi
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Matsuyama
authors.forename: Susumu
authors.initials: S
authors.lastname: Eguchi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D003082:Colectomy / Q000009:adverse effects / Q000401:mortality; D015179:Colorectal Neoplasms / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D055088:Early Detection of Cancer / Q000379:methods; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; C117307:KRAS protein, human; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D016283:Proto-Oncogene Proteins p21(ras)